EUCTR2010-018363-42-IT进行中（未招募）不适用
A phase II dose finding study of induction cisplatin, docetaxel and escalating doses of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck squamous cell carcinoma - DOXERT 1
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE0 个研究点开始时间: 2010年12月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Hystologically or cytologically confirmed HNC with exclusion of the nasopharynx 2.Locally advanced inoperable disease 3.age > 18 years 4.ECOG PS: 0-1 5.Life expectancy at least 3 months at study entrance 6.Normal bone marrow reserve (absolute neuthrophil count > 1500/mm3; platelets > 100000/mm3; haemoglobin > 9 g/dl) 7.Normal hepatic function (total serum bilirubin < 1.5 x upper limit of normal; liver transaminases > 3 x upper limit of normal) 8.Normal renal function (serum creatinine < 1,25 x upper limit of normal and creatinine clearance > 60 ml/min). 9.Normal cardiac function (assessed by ECG and ecocardiography with ejection fraction > 50%) 10.No pregnancy 11.No prior chemo or radiotherapy 12.Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Concomitant treatment with investigation agents 2.Nasopharygeal carcinoma 3.Brain metastases (CT scan or MRI required only in case of clinical suspicion of CNS metastases) 4.Second malignancies 5.History of myocardial infarction within the last 12 months
研究者
相似试验
招募中
2 期
A phase II study of Conbination therapy of Cisplatin/Pemetrexed/Bavacizumab in previously untreated patients with StageIIIB/IV or recurrent disease nonsquamous non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000006874Fukushima medical University37
已完成
不适用
A phase I dose escalation study of cisplatin, pemetrexed and radiotherapy for inoperable stage III non-small cell lung cancerung cancerCancerLung cancerISRCTN91946477Erasmus Medical Center (The Netherlands)39
尚未招募
1 期
A Phase I Dose Fnding Study of Weekly Cisplatin Plus S-1 with Concurrent Proton-beam (or Photon) Therapy for Elderly Patients with Inoperable Stage III Non-Small Cell Lung Cancer.Inoperable stage III Non-small Cell Lung Cancerelderly patients, inoperable stage III NSCLC, weekly cisplatin plus S1, concurrent chemo-radiotherapyJPRN-jRCT1041230096Akita Kenji12
进行中（未招募）
不适用
A Phase II study evaluating the role of the combination of cisplatin and cyclophosphamide administered metronomically in patients with advanced breast cancer triple negative (Estrogen and progesterone receptors negative and c-erb B2 non overexpressed).Advanced, triple receptor negative breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020835-38-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
1 期
Phase Ib study of combination therapy with Cisplatin, Irinotecan, and Ramucirumab for extensive-disease small-cell lung cancerExtensive disease small cell lung cancerJPRN-UMIN000032671Shizuoka Cancer Center10